The scientific objective of the project led by professor Agnieszka Basta-Kaim of the Institute of Pharmacology of the Polish Academy of Sciences together with an Italian team is to verify the hypothesis that the enhancement of endogenous mechanisms of extinction/termination of long-term inflammation (RoI) may constitute an innovative therapeutic approach (pharmacotherapy of resolution) in the treatment of central nervous system (CNS) diseases.

The special importance of innovative research conducted should be considered in the conext of diseases characterized by chronic inflammation of the nervous system, such as neurodegenerative diseases (Alzheimer's disease, Parkinson's disease) and mental illnesses - depression, schizophrenia. All of them have become an exremly important medical problem in recent years, as well as a global social and economic burden.

So far, the collaboration has led to the identification of new FPR2 agonists with anti-inflammatory and pro-resolving properties in in vivo and ex vivo models of neuroinflammation. These results have led to collaborative research projects funded by aimed at assessing the therapeutic potential of FPR2 agonists in Alezheimer's disease or depression. The Italian Unit has experience in the development of "drug-like" molecules for in vivo studies, while the Polish Unit hasexperience in studying the biochemical mechanisms of CNS immune response and behavioral properties of potential drugs. 

The mobility program Canaletto strenghtens the collaboration between the partners and gives young researchers the opportunity to conduct research in a multidisciplinary enviroment.